Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion

Core Insights - Eli Lilly has agreed to acquire Centessa Pharmaceuticals for an initial $6.3 billion, enhancing its neuroscience portfolio and capabilities in sleep medicine [1] Company Summary - The acquisition of Centessa Pharmaceuticals represents a strategic move for Eli Lilly to expand its offerings in the neuroscience sector [1] - The deal is expected to bolster Eli Lilly's research and development capabilities in sleep-related treatments [1] Industry Summary - This acquisition highlights the growing interest and investment in the neuroscience and sleep medicine markets, indicating potential growth opportunities within these sectors [1]